Bladder Cancer

P=N/A, N=500, Active, not recruiting, Oslo University Hospital

P2, N=15, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Jul 2026 --> Jul 2027

In this Egyptian cohort, Ki-67 ≥ 30% was strongly associated with adverse pathological features and independently predicted high-grade disease, supporting its use as a practical ancillary marker and providing regional validation of prior reports. Vimentin was not significantly associated with the studied parameters in this dataset. Future studies should assess alternative cutoffs within the same cohort and validate outcome-linked thresholds in longitudinal datasets.

SSD inhibits the malignant phenotype of BCa by targeting PI3K/AKT to trigger ferroptosis. Its synergistic effect with GEM from the dual mechanisms of ferroptosis sensitization and epithelial-mesenchymal transition inhibition, providing an innovative combination strategy based on natural product active ingredients to overcome bladder cancer chemoresistance.

P=N/A, N=2000, Recruiting, Alliance for Clinical Trials in Oncology | Trial primary completion date: Jan 2026 --> Jan 2027

P=N/A, N=240, Completed, University of Pisa

TNFRSF17 serves as a potential marker to characterize an immune-distinct and prognostically favorable subgroup within CD274High tumors, and to refine stratification for ICB.

Owing to the fact that the Editorial Office has been made aware of potential issues surrounding the scientific integrity of this paper, we are issuing an Expression of Concern to notify readers of this potential problem while the Editorial Office continues to investigate this matter further. [Oncology Reports 35: 1375‑1384, 2016; DOI: 10.3892/or.2015.4492].

It promotes malignant development and immune microenvironment remodeling through the MAPK pathway. Pathological analysis can predict PSMD2 expression, offering valuable insights into immunotherapy responses and survival outcomes.

The exosome levels in smoke were significantly lower than that in controls. Based on these findings, we concluded that the surgical smoke produced during RARC does not contain cancer cells, genes, or exosomes.

Our results indicate that early-onset bladder cancer is a distinct patient population that has disease driven by specific somatic mutations, some of which represent therapeutic targets. This suggests potential benefits of genomic tumor profiling in guiding personalized treatment.